Zanamivir for the treatment of avian influenza infections in humans.

Expert Rev Clin Pharmacol

The University of Melbourne, Department of Pharmacology, Melbourne. 160 Winmalee Road, Balwyn, Victoria, 3103, Australia.

Published: January 2010

Zanamivir is currently not recommended by the WHO for the first-line treatment of human influenza A (H5N1) infections. Zanamivir pharmacokinetics and antiviral efficacy were reviewed to assess the basis for this recommendation. Following inhalation of 10 mg zanamivir in healthy humans, the drug is widely distributed throughout the lungs. Mean lung sputum concentrations of zanamivir are 1441 and 235 ng/ml at 6 and 12 h postinhalation, respectively. Following repeated dosing to patients, mean steady-state C(max) and C(min) plasma zanamivir concentrations are approximately 60 and 4 ng/ml, respectively. Zanamivir has high in vitro activity against H5N1 strains isolated from patients (IC(50) 0.3-0.7 ng/ml) including oseltamivir-resistant strains. These data support a reassessment of zanamivir's role in the treatment of human H5N1 infections.

Download full-text PDF

Source
http://dx.doi.org/10.1586/ecp.09.60DOI Listing

Publication Analysis

Top Keywords

treatment human
8
h5n1 infections
8
zanamivir
7
zanamivir treatment
4
treatment avian
4
avian influenza
4
influenza infections
4
infections humans
4
humans zanamivir
4
zanamivir currently
4

Similar Publications

Objective: This ancillary study's purpose is to describe the relationship between dose of treatment and body mass index (BMI) outcomes in a tele-behavioral health program delivered in the IDeA States Pediatric Clinical Trials Network to children and their families living in rural communities.

Methods: Participants randomized to the intervention were able to receive 26 contact hours (15 hr of group sessions and 11 hr of individual sessions) of material focused on nutrition, physical activity, and behavioral caregiver training delivered via interactive televideo. Dose of the intervention received by child/caregiver dyads (n = 52) from rural areas was measured as contact hours.

View Article and Find Full Text PDF

Transformers for Neuroimage Segmentation: Scoping Review.

J Med Internet Res

January 2025

Department of Computer Science and Software Engineering, United Arab Emirates University, Al Ain, United Arab Emirates.

Background: Neuroimaging segmentation is increasingly important for diagnosing and planning treatments for neurological diseases. Manual segmentation is time-consuming, apart from being prone to human error and variability. Transformers are a promising deep learning approach for automated medical image segmentation.

View Article and Find Full Text PDF

Background: TheKeep.Ca was built to facilitate engagement with those experiencing cancer in Manitoba, Canada. Constructed between 2020 and 2024 with a group of patient advisors, the website includes information on engagement activities including research participation, the patient advisor role, and how those experiencing cancer can access these Manitoba activities.

View Article and Find Full Text PDF

Background: The neonatal mortality rate in Pakistan is the third highest in Asia, with 8.6 million preterm babies. These newborns require warmth, nutrition, and infection protection, typically provided by incubators.

View Article and Find Full Text PDF

This study provides preliminary evidence for real-time functional magnetic resonance imaging neurofeedback (rt-fMRI NF) as a potential intervention approach for internet gaming disorder (IGD). In a preregistered, randomized, single-blind trial, young individuals with elevated IGD risk were trained to downregulate gaming addiction-related brain activity. We show that, after 2 sessions of neurofeedback training, participants successfully downregulated their brain responses to gaming cues, suggesting the therapeutic potential of rt-fMRI NF for IGD (Trial Registration: ClinicalTrials.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!